Alphabet drives cloud and AI momentum, Exxon Mobil boosts energy projects, and AbbVie rides strong drug launches despite ...

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

AbbVie Inc. (NYSE:ABBV) on Thursday released topline results from the second of two pivotal studies of the Phase 3 UP-AA clinical program evaluating the safety and efficacy of upadacitinib (RINVOQ; 15 ...

AbbVie Inc. (NYSE:ABBV) reported fourth-quarter revenue of $15.1 billion, reflecting a 5.6% YoY increase and surpassing analysts’ expectations of $14.87 billion.

AbbVie is expected to post earnings of $2.90 per share for the current quarter, representing a year-over-year change of +3.9%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.4%.

Shares of AbbVie Inc. ABBV rose 1.42% to $201.47 Wednesday, on what proved to be an all-around positive trading session for ...

AbbVie Inc.'s Q2 2025 results showcase Skyrizi & Rinvoq's growth, strong finances, and a promising pipeline. Click for my ...

AbbVie to Buy Cancer Treatment Start-Up AbbVie agreed to pay $5.8 billion to acquire Stemcentrx as it continues its big push into cancer treatment. By Michael J. de la Merced and Andrew Pollack ...

AbbVie reported revenues of $15.1 billion in the last reported quarter, representing a year-over-year change of +5.6%. EPS of $2.16 for the same period compares with $2.79 a year ago.

Go Higher. AbbVie’s anti-inflammatory drug Humira was never cheap, selling for about $19,000 a year in 2012. It’s gone up by 100 percent since then. By Danny Hakim ...